DuPont touts favorable Cardiolite studies
Studies presented at this month’s American Heart Association meeting in Atlanta suggest that heart scans conducted with Cardiolite, a myocardial perfusion agent from North Billerica, MA-based Du Pont, may help clinicians predict a patient’s
Studies presented at this months American Heart Association meeting in Atlanta suggest that heart scans conducted with Cardiolite, a myocardial perfusion agent from North Billerica, MA-based Du Pont, may help clinicians predict a patients risk of future cardiac events and avoid performing invasive procedures. Researchers at Cedars Sinai Medical Center used Cardiolite in SPECT scans on 2600 patients to evaluate whether assessing cardiac function and perfusion would help predict the likelihood of both fatal and nonfatal heart attacks. The team found that cardiac functionthe blood volume passing through the heartis a strong cardiac death indicator, while perfusionblood flow to the heart tissueis a strong nonfatal heart attack risk indicator. The group surmised that evaluating these two factors could increase physicians accuracy in assessing a patients future heart attack risk.
In another study, conducted at the Medical College of Virginia, researchers used Cardiolite in the emergency room to assess whether patients with chest pain required coronary angiography. The 1000-patient study showed that fewer patients required the procedure when Cardiolite was used to appraise their condition. In a related study at MCV, 600 patients with chest pain but at low risk for heart attack were assessed with a Cardiolite scan, allowing clinicians to evaluate the extent of heart damage without more invasive testing.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
New MRI Study Questions Use of Corticosteroid Injections for Knee OA
May 27th 2025Two years after intraarticular knee injections for knee osteoarthritis (OA), study participants who had corticosteroid knee injections had greater OA progression than control patients while the use of hyaluronic acid injections was associated with less OA progression.
